Screener
SG&A at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The source filing: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001232524-26-000025
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Total revenues | 1,068.9 | 897.8 |
| Operating expenses: | ||
| Cost of product sales (excluding amortization of acquired developed technologies) | 134.1 | 104.6 |
| Selling, general and administrative | 352.7 | 514.0 |
| Research and development | 196.0 | 180.7 |
| Intangible asset amortization | 172.3 | 154.4 |
| Gain on sale of priority review voucher | (122.8) | — |
| Total operating expenses | 732.3 | 953.7 |
Item 1.Financial Statements
FAQ
- What is Jazz Pharmaceuticals's SG&A?
- Jazz Pharmaceuticals (JAZZ) reported SG&A of $352.7M in Q1 2026.
- How has Jazz Pharmaceuticals's SG&A changed year-over-year?
- Jazz Pharmaceuticals's SG&A decreased by 31.4% year-over-year, from $514M to $352.7M.
- What is the long-term trend for Jazz Pharmaceuticals's SG&A?
- Over 4 years (2021 to 2025), Jazz Pharmaceuticals's SG&A has grown at a 5.7% compound annual growth rate (CAGR), from $1.45B to $1.81B.
- What does SG&A mean?
- Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.
Ask your AI about Jazz Pharmaceuticals's sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude